Aug 2026· Journal of Thoracic Oncology· pp.
104165
· 0 citations
Medicine
TL;DR
Findings support sutetinib as a potential treatment option for this molecularly heterogeneous population of adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations and demonstrate clinically meaningful antitumor activity with a manageable safety profile.
Abstract
Purpose
Uncommon epidermal growth factor receptor (EGFR) mutations account for ∼10% of EGFR-altered non-small cell lung cancer (NSCLC) and show heterogeneous sensitivity to EGFR-tyrosine kinase inhibitors (TKIs), with limited prospective evidence to inform first-line therapy. Sutetinib is an irreversible EGFR-TKI. We assessed the safety and antitumor efficacy of sutetinib in patients with locally advanced or metastatic NSCLC with uncommon EGFR mutations.
Methods
In this multicenter, open-label, single-arm phase IIb trial, adults with locally advanced or metastatic NSCLC harboring EGFR G719X, S768I, L861Q, or predefined compound mutations and no prior EGFR-TKI therapy were enrolled. Patients received sutetinib 80 mg orally once daily in 28-day cycles until radiographic progression or unacceptable toxicity. Patients who received at least one dose of treatment and evaluable for efficacy analysis were included in the primary analysis, and all patients who received at least one dose of treatment were included in the safety analysis. The primary endpoint was objective response rate (ORR), as assessed by the independent review committee (IRC). Secondary endpoints included duration of response (DoR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and safety.
Results
From December 9, 2021, to May 5, 2024, 99 patients were enrolled (efficacy-evaluable, n=96; safety, n=99). As of data cut-off in October, 2024, the median follow-up was 16.6 months. The IRC-confirmed ORR was 70.8% (95% confidence interval [CI], 60.7-79.7) and the DCR was 90.6% (95% CI, 82.9-95.6). Median DoR was 12.0 months (95% CI, 9.3-15.7) and median PFS was 13.7 months (95% CI, 10.9-16.4). Median OS was not reached (95% CI, 22.2-not reached). ORR was numerically higher in patients with compound versus solitary uncommon EGFR mutations (84.4% vs 64.1%), with median PFS of 13.8 versus 11.0 months, respectively. Treatment-related adverse events (TRAEs) of any grade occurred in 97.0% (96/99) of patients, and grade ≥3 TRAEs occurred in 42.4% (42/99). The most common grade ≥3 TRAEs were diarrhea (28.3% [28/99]), hypokalemia (8.1% [8/99]), and increased gamma-glutamyl transferase (5.1% [5/99]). TRAEs led to dose reduction in 34.3% (34/99) and treatment discontinuation in 4.0% (4/99). No treatment-related deaths occurred.
Conclusions
Sutetinib met the prespecified primary endpoint and demonstrated clinically meaningful antitumor activity with a manageable safety profile in advanced NSCLC harboring uncommon EGFR mutations (G719X, S768I, and L861Q). These findings support sutetinib as a potential treatment option for this molecularly heterogeneous population.
TRIAL REGISTRATION
NCT05168566.
Mefatinib demonstrated superior efficacy to gefitinib with a similar tolerability profile in the first-line treatment of EGFR-mutated advanced NSCLC with common and uncommon EGFR-activating mutations.
Jia Yu, Anwen Xiong, Qi-Ming Wang et al.· Signal Transduction and Targ...· 0 citations
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have provided significant clinical benefit to patients with EGFR-mutant non-small cell lung cancer (NSCLC), but multiple concurrent genetic alterations may limit their efficacy. We report a case of advanced lung adenocarcinoma harboring concurrent...
Lin Zhang, Chuan-Tao Zhang, Hui-Yun Wang et al.· Frontiers in Oncology· 0 citations
This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.
X. Le, A. Passaro, Yuan-Yuan Zhao et al.· The Lancet Oncology· 0 citations
BACKGROUND
MET and angiogenic pathways are activated in EGFR-mutant non-small-cell lung cancer (NSCLC) upon resistance to tyrosine-kinase inhibitors (TKIs). Amivantamab, an EGFR and MET bispecific antibody, is approved in combination with chemotherapy for EGFR-mutant NSCLC post-osimertinib progression based on results...
R. Soo, Sanjay Popat, U. Dafni et al.· The Lancet Respiratory Medic...· 0 citations
Osimertinib exhibited meaningful differences in efficacy and resistance mechanisms across distinct ucEGFR mut, and ex19 delins showed comparable survival outcomes and resistance patterns to classical ex19 deletions, albeit with heterogeneous osimertinib sensitivity depending on the deletion–insertion starting codon.
G. Farinea, A. Mogavero, A. Vitale et al.· ESMO Open· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.